PMID- 23178094
OWN - NLM
STAT- MEDLINE
DCOM- 20130619
LR  - 20131121
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 22
IP  - 16
DP  - 2012 Dec
TI  - [Diagnosis and management of adverse events occuring during BCG therapy for 
      non-muscle invasive bladder cancer (NMIBC): review of the Cancer Committee of the 
      French Association of Urology].
PG  - 989-98
LID - S1166-7087(12)00191-1 [pii]
LID - 10.1016/j.purol.2012.04.019 [doi]
AB  - INTRODUCTION: Intravesical BCG immuno-therapy with maintenance therapy is 
      considered as the standard treatment for non-muscle invasive bladder cancer with 
      high risk of recurrence and progression. In practice, adverse events (AEs) of BCG 
      therapy could restrict its prescription by urologists. The aim of this article 
      was to present a review of these AEs and of their management. MATERIALS AND 
      METHODS: A bibliographic research in French and English using Medline((R)) and 
      Embase((R)) with the keywords "BCG", "bladder", "complication", "toxicity", 
      "adverse reaction", "prevention" and "treatment" was performed. RESULTS: The main 
      mechanism of AEs of BCG are infectious (cystitis, fever), immuno-allergic 
      (granulomatous prostatitis, epididymo-orchitis, and granulomatous reactions) and 
      auto-immune (arthralgies, rash). Management of AEs is based on their 
      pathophysiological mechanisms. Classifications of BCG therapy AEs based on 
      clinical features allow to adapt their treatments. CONCLUSION: The combination of 
      antibiotics directed against BCG, steroid or non-steroidal anti-inflammatory 
      medication and symptomatic treatment is currently the triad on which is set up 
      the appropriate treatment of severe AEs. Reductions of BCG doses and ofloxacin 
      medication after instillation decrease the frequency and severity of minor and 
      moderate AEs. Severe or more than 7 days long infectious AEs, immuno-allergic AEs 
      or auto-immune during more than 7 days impose cessation of BCG immuno-therapy.
CI  - Copyright (c) 2012 Elsevier Masson SAS. All rights reserved.
FAU - Neuzillet, Y
AU  - Neuzillet Y
AD  - Service d'urologie, universite de Versailles-Saint-Quentin-en-Yvelines, hopital 
      Foch, Suresnes, France. y.neuzillet@hopital-foch.org
FAU - Roupret, M
AU  - Roupret M
FAU - Wallerand, H
AU  - Wallerand H
FAU - Pignot, G
AU  - Pignot G
FAU - Larre, S
AU  - Larre S
FAU - Irani, J
AU  - Irani J
FAU - Davin, J-L
AU  - Davin JL
FAU - Moreau, J-L
AU  - Moreau JL
FAU - Soulie, M
AU  - Soulie M
FAU - Pfister, C
AU  - Pfister C
CN  - le comite de cancerologie de l'association francaise d'urologie
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Diagnostic et prise en charge des evenements indesirables survenant au decours 
      des instillations endovesicales de BCG pour le traitement des tumeurs de vessie 
      n'infiltrant pas le muscle (TVNIM) : revue du comite de cancerologie de 
      l'Association francaise d'urologie.
DEP - 20120728
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Anti-Infective Agents, Urinary)
RN  - 0 (BCG Vaccine)
RN  - A4P49JAZ9H (Ofloxacin)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/*adverse effects
MH  - Administration, Intravesical
MH  - Anti-Infective Agents, Urinary/*therapeutic use
MH  - Arthralgia/diagnosis/immunology
MH  - BCG Vaccine/administration & dosage/*adverse effects
MH  - Cystitis/*diagnosis/drug therapy/immunology
MH  - Drug Administration Schedule
MH  - Epididymitis/diagnosis/drug therapy/immunology
MH  - Fever/immunology
MH  - France
MH  - Granuloma/diagnosis/immunology
MH  - Humans
MH  - Male
MH  - Neoplasm Invasiveness
MH  - Ofloxacin/*therapeutic use
MH  - Orchitis/diagnosis/drug therapy/immunology
MH  - Practice Guidelines as Topic
MH  - Prostatitis/*diagnosis/drug therapy/immunology/pathology
MH  - Societies, Medical
MH  - Urinary Bladder Neoplasms/*drug therapy/immunology/pathology
MH  - Urology
EDAT- 2012/11/28 06:00
MHDA- 2013/06/20 06:00
CRDT- 2012/11/27 06:00
PHST- 2012/03/06 00:00 [received]
PHST- 2012/03/13 00:00 [revised]
PHST- 2012/04/01 00:00 [accepted]
PHST- 2012/11/27 06:00 [entrez]
PHST- 2012/11/28 06:00 [pubmed]
PHST- 2013/06/20 06:00 [medline]
AID - S1166-7087(12)00191-1 [pii]
AID - 10.1016/j.purol.2012.04.019 [doi]
PST - ppublish
SO  - Prog Urol. 2012 Dec;22(16):989-98. doi: 10.1016/j.purol.2012.04.019. Epub 2012 
      Jul 28.